V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Arrowhead Pharmaceuticals Executive Compensation (FY25)

ARWR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Christopher Anzalone
Latest say-on-pay support
=
March 19, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Arrowhead Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): March 20, 2026
16 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Arrowhead Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
262 figures on this page: 251 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christopher Anzalone: $12,423,473 → $9,029,861 (27.3% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Arrowhead Pharmaceuticals' chief executive and what were they paid?
Christopher Anzalone, President and Chief Executive Officer, received $9,029,861 in total compensation for fiscal 2025. Anzalone's total moved 27.3% lower from the $12,423,473 reported for fiscal 2024.
What was Arrowhead Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 41.0% of votes cast for or against in favor at the meeting held March 19, 2026 for fiscal 2025.
Which companies are in Arrowhead Pharmaceuticals' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals, Inc., Amicus Therapeutics, AnaptysBio, Apellis Pharmaceuticals and Arcus Biosciences, among others.
What is Arrowhead Pharmaceuticals' chief executive pay ratio?
The company reported a chief executive pay ratio of 55:1 for fiscal 2025, against median employee compensation of $163,062.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Anzalone
President and Chief Executive Officer
◇—◇—◇—◇◇
Kenneth Myszkowski
Chief Financial Officer
◇—◇—◇—◇◇
Patrick O'Brien
Chief Operating Officer and General Counsel
◇—◇—◇—◇◇
James Hamilton
Chief of Discovery and Translational Medicine
◇—◇—◇—◇◇
Tracie Oliver
Chief Commercial Officer
◇◇◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Anzalone
President and Chief Executive Officer
◇—◇—◇—◇◇
Patrick O'Brien
Chief Operating Officer and General Counsel
◇—◇—◇—◇◇
Kenneth Myszkowski
Chief Financial Officer
◇—◇—◇—◇◇
Javier San Martin
Chief Medical Officer
◇—◇—◇—◇◇
James Hamilton
Chief of Discovery and Translational Medicine
◇—◇—◇—◇◇
Tracie Oliver
Former Chief Commercial Officer
◇◇◇—◇—◇— not reconciled
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Anzalone
President and Chief Executive Officer
◇—◇—◇—◇◇
Patrick O'Brien
Chief Operating Officer and General Counsel
◇—◇—◇—◇◇
Kenneth Myszkowski
Chief Financial Officer
◇—◇—◇—◇◇
James Hamilton
Chief of Discovery and Translational Medicine
◇—◇—◇—◇◇
Javier San Martin
Former Chief Medical Officer
Departed during or after this year
◇—◇———◇◇
Tracie Oliver
Former Chief Commercial Officer
Departed during or after this year
◇—◇———◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Anzalone
President and Chief Executive Officer
◇—◇—◇—◇◇
Patrick O'Brien
Chief Operating Officer
◇—◇—◇—◇◇
James Hamilton
Chief Medical Officer
◇—◇—◇—◇◇
Kenneth Myszkowski
Former Chief Financial Officer
Departed during or after this year
◇—◇—◇—◇◇
Tracie Oliver
Former Chief Commercial Officer
Departed during or after this year
◇——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher AnzalonePSU◇—◇———◇
Christopher AnzaloneRSU◇——◇——◇
Christopher AnzaloneRSU◇——◇——◇
Daniel ApelRSU◇——◇——◇
James HamiltonRSU◇——◇——◇
Kenneth MyszkowskiRSU◇——◇——◇
Patrick O BrienRSU◇——◇——◇
Patrick O’BrienRSU◇——◇——◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
James HamiltonRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Kenneth MyszkowskiRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Patrick O'BrienRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Christopher AnzaloneRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/1/2026
PSU◇◇——
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christopher Anzalone
President and Chief Executive Officer · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-solicit period◇
Kenneth Myszkowski
Former Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance base◇
Severance cash amount◇
Equity acceleration on change in control◇
Benefits continuation◇
Tracie Oliver
Former Chief Commercial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Change-in-control trigger◇
Equity acceleration on change in control◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas Ingram
◇◇————◇
William Waddill
◇◇————◇
Michael S. Perry
◇◇————◇
Victoria Vakiener
◇◇————◇
Mauro Ferrari
◇◇————◇
Adeoye Olukotun
◇◇————◇
Hongbo Lu
◇◇————◇
Douglass Given
◇—————◇
Christopher Anzalone served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals, Inc. ACAD
  • Amicus Therapeutics FOLD
  • AnaptysBio ANAB
  • Apellis Pharmaceuticals APLS
  • Arcus Biosciences RCUS
  • BioCryst Pharmaceuticals BCRX
  • Blueprint Medicines BPMC
  • BridgeBio Pharma BBIO
  • CRISPR Therapeutics AG CRSP
  • Day One Biopharmaceuticals DAWN
  • Denali Therapeutics DNLI
  • Halozyme Therapeutics HALO
  • IDEAYA Biosciences IDYA
  • Intellia Therapeutics NTLA
  • Ionis Pharmaceuticals IONS
  • Ironwood Pharmaceuticals IRWD
  • Madrigal Pharmaceuticals MDGL
  • Prothena symbol not shown
  • Ultragenyx Pharmaceuticals RARE
  • Vir Biotechnology VIR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025March 19, 2026=◇◇◇
2024March 12, 2025=◇◇◇
2023March 14, 2024=◇◇◇
2022March 16, 2023=◇◇◇
2021March 17, 2022=◇◇◇
2020March 18, 2021=◇◇◇
2019March 19, 2020=◇◇◇
2018March 15, 2019=◇◇◇
2017March 16, 2018=◇◇◇
2016March 21, 2017=◇◇◇
2015March 8, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Christopher Anzalone (President and Chief Executive Officer), FY2025 total compensation $9,029,861 (base salary $981,046) [exec_comp, SEC accession 0000879407-26-000019, filed 2026-01-27]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Arrowhead Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Arrowhead Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arrowhead Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Arrowhead Pharmaceuticals recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Arrowhead Pharmaceuticals' disclosed peer group is defensible, who names Arrowhead Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
262 figures on this page: 251 cited to the filing that reported them, 11 calculated from figures it prints.
251 cited to the filing
11 calculated from the filing

Documents cited

  1. 0000879407-26-000037
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000879407-26-000019
    Compensation Discussion and Analysis · Compensation Tables · Director Compensation · EACH OF THE NOMINEES FOR DIRECTOR IN PROPOSAL ONE. · and 3 more sections
  3. 0001628280-25-024666
    Exhibit
  4. 0001628280-25-013619
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001628280-25-002848
    Compensation Tables
  6. 0001628280-24-011930
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001628280-24-002375
    Compensation Tables
  8. 0001628280-23-008639
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001628280-23-001743
    Compensation Tables
  10. 0001193125-22-079575
  11. 0001564590-21-015147
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001564590-20-011831
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-19-076873
  14. 0001193125-18-088148
  15. 0001193125-17-092797
  16. 0001193125-16-500107
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arrowhead Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ARWR (accessed 2026).
Short form: data: Velarion

The Arrowhead Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
16 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arrowhead Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Arrowhead Pharmaceuticals discloses

The companies named in ARWR's own disclosed peer group.

ACADIA Pharmaceuticals, Inc.Amicus TherapeuticsAnaptysBioApellis PharmaceuticalsArcus BiosciencesBioCryst PharmaceuticalsBlueprint MedicinesBridgeBio PharmaCRISPR Therapeutics AGDay One BiopharmaceuticalsDenali TherapeuticsHalozyme TherapeuticsIDEAYA BiosciencesIntellia TherapeuticsIonis PharmaceuticalsIronwood PharmaceuticalsMadrigal PharmaceuticalsUltragenyx PharmaceuticalsVir Biotechnology

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy